Merck to built new pharmaproduction
Merck to Invest € 250 Million in Production Value Chain in China
Significant investment in Life Science
Currently China sees a growing need to strengthen the technologies and processes involved in developing and manufacturing healthcare products in an effort to ensure more competitive productivity, efficacy and safety. As a leading innovator in the pharmaceutical and biopharmaceutical industry, the Life Science business is committed to playing an active role in China’s transformation into an innovation-driven economy.
Today’s announcement of the around € 80 million investment in the Life Science Center - Nantong demonstrates Merck’s commitment to supporting the industry’s fast growth by providing a wide range of leading, innovative solutions for customers and partners in China.
The planned facility will reinforce Merck’s leading position in inorganic salts for active pharmaceutical ingredients and excipients and cell culture media (CCM) for the pharmaceutical, biopharma and healthcare markets in China as well as ready-to-use (RTU) media for environmental and sterility testing.
To reinforce its position in China, Merck has continuously invested in China in recent years. Apart from the investments announced today, this includes significant investments in Merck’s third business sector Performance Materials in projects such as the Liquid Crystal Center in 2013 (investment volume of more than € 30 million) and the Shanghai Display Materials R&D Center in 2015 (investment volume of more than € 5 million).
In 2015, the Asia-Pacific region accounted for 33% of Merck’s sales (€ 4.2 billion, up 23% from 2014). All three business sectors, which have more than 3,100 employees, made positive contributions to the company’s overall organic sales growth in China.